chartexchange

Stock Market Today, Nov. 18: Recursion Pharmaceuticals Rises 4% on FDA Alignment for REC-4881 Phase 3 Design

The Motley Fool | Nov 18, 2026 5:20 PM EST

Recursion Pharmaceuticals (NASDAQ:RXRX) , an AI-enabled clinical-stage drug discovery company, closed at $2.83, up 3.86%. The stock rose after the company said it reached FDA alignment on the REC-4881 Phase 3 design, and investors are watching for further regulatory detail. Trading volume reached 39.4M shares, coming in about 65% above its three-month average of 23.8M shares. Recursion Pharmaceuticals IPO'd in 2021 and has fallen 91% since going public. S&P 500 (SNPINDEX:^GSPC) closed at 7,323, down 0.24%, while Nasdaq Composite (NASDAQINDEX:^IXIC) finished at 24,430, up 0.42%. In biotechnology : AI-enabled drug discovery and clinical-stage therapeutics, Schrödinger (NASDAQ:SDGR) closed at $27.20, up 6.00%, and Relay Therapeutics (NASDAQ:RLAY) closed at $16.51, up 0.24%. Recursion shares are up 4% today after it aligned with the FDA on a Phase III trial design for 200 adults with familial adenomatous polyposis. The disease currently has no approved therapies, making Recursion's REC-4881 one of the first AI-enabled treatments to advance toward a Phase III trial. Continue reading

Read original article